| Person-years | All-cause mortality | Breast cancer mortality | Cardiovascular disease mortality | |||
---|---|---|---|---|---|---|---|
 |  | Deaths | HR (95% CI)a | Deaths | HR (95% CI)b | Deaths | HR (95% CI)b |
Follow-up period: | Â | Â | Â | Â | Â | Â | Â |
5-year mortality | Â | Â | Â | Â | Â | Â | Â |
 Intact uterus and ovaries, never hormone use | 15,462 | 537 | 1 | 331 | 1 | 59 | 1 |
 TAHBSOc | 6,165 | 170 | 0.93 (0.78, 1.10) | 103 | 0.93 (0.74, 1.16) | 19 | 0.94 (0.55, 1.58) |
  TAHBSO, Never used hormones | 1,857 | 64 | 0.91 (0.70, 1.19) | 31 | 0.79 (0.54, 1.16) | 10 | 1.14 (0.58, 2.24) |
  TAHBSO, Used unopposed estrogens | 3,596 | 90 | 0.93 (0.75, 1.17) | 61 | 1.03 (0.77, 1.36) | 7 | 0.70 (0.32, 1.55) |
Mortality among 5-year survivors | Â | Â | Â | Â | Â | Â | Â |
 Intact uterus and ovaries, never hormone use | 27,759 | 1,340 | 1 | 330 | 1 | 267 | 1 |
 TAHBSOc | 11,384 | 387 | 0.80 (0.72, 0.90) | 95 | 0.81 (0.64, 1.02) | 75 | 0.82 (0.63, 1.06) |
  TAHBSO, Never used hormones | 3,541 | 177 | 0.82 (0.78, 1.07) | 28 | 0.69 (0.46, 1.01) | 48 | 1.19 (0.87, 1.63) |
  TAHBSO, Used unopposed estrogens | 6,649 | 180 | 0.72 (0.62, 0.85) | 59 | 0.92 (0.69, 1.23) | 24 | 0.53 (0.35, 0.81) |
Age at diagnosis: | Â | Â | Â | Â | Â | Â | Â |
50-64 years d | Â | Â | Â | Â | Â | Â | Â |
 Intact uterus and ovaries, never hormone use | 20,968 | 593 | 1 | 326 | 1 | 60 | 1 |
 TAHBSOc | 9,559 | 189 | 0.78 (0.66, 0.91) | 103 | 0.78 (0.62, 0.98) | 15 | 0.61 (0.34, 1.09) |
  TAHBSO, Never used hormones | 1,890 | 47 | 0.80 (0.59, 1.08) | 22 | 0.68 (0.43, 1.07) | 6 | 0.97 (0.42, 2.24) |
  TAHBSO, Used unopposed estrogens | 6,391 | 115 | 0.75 (0.61, 0.92) | 68 | 0.85 (0.65, 1.12) | 5 | 0.32 (0.13, 0.80) |
≥ 65 years |  |  |  |  |  |  |  |
 Intact uterus and ovaries, never hormone use | 22,253 | 1,284 | 1 | 335 | 1 | 296 | 1 |
 TAHBSOc | 7,990 | 368 | 0.86 (0.77, 0.97) | 95 | 0.95 (0.75, 1.20) | 79 | 0.90 (0.69, 1.15) |
  TAHBSO, Never used hormones | 3,507 | 194 | 0.95 (0.82, 1.11) | 37 | 0.76 (0.54, 1.08) | 52 | 1.21 (0.89, 1.64) |
  TAHBSO, Used unopposed estrogens | 3,854 | 155 | 0.80 (0.67, 0.94) | 52 | 1.15 (0.85, 1.54) | 26 | 0.65 (0.43, 0.98) |